Filing Details
- Accession Number:
- 0001209191-18-034622
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-01 15:37:48
- Reporting Period:
- 2018-05-30
- Accepted Time:
- 2018-06-01 15:37:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1659323 | Iterum Therapeutics Plc | ITRM | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1734389 | Mark Chin | C/O Iterum Therapeutics Plc, Blk 2 Fl. 3, Harcourt Centre, Harcourt St. Dublin L2 2 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2018-05-30 | 445,576 | $0.00 | 445,576 | No | 4 | C | Indirect | By Arix Bioscience Holdings Ltd. |
| Ordinary Shares | Acquisiton | 2018-05-30 | 248,721 | $0.00 | 694,297 | No | 4 | C | Indirect | By Arix Bioscience Holdings Ltd. |
| Ordinary Shares | Acquisiton | 2018-05-30 | 337,606 | $13.00 | 1,031,903 | No | 4 | P | Indirect | By Arix Bioscience Holdings Ltd. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By Arix Bioscience Holdings Ltd. |
| No | 4 | C | Indirect | By Arix Bioscience Holdings Ltd. |
| No | 4 | P | Indirect | By Arix Bioscience Holdings Ltd. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Series B-1 Preferred Shares | Disposition | 2018-05-30 | 445,576 | $0.00 | 445,576 | $0.00 |
| Ordinary Shares | Series B-2 Preferred Shares | Disposition | 2018-05-30 | 248,721 | $0.00 | 248,721 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- The Reporting Person is an Investment Director for By Arix Bioscience Holdings Ltd.
- The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- Not applicable.
Billionaire Hedge Funds
